ReviewBritish journal of clinical pharmacology2014
Substandard drugs: a potential crisis for public health.
Review in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Substandard and falsified antimicrobials in selected east African countries: A systematic review.PloS one · 2024Pooled it
- Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.The American journal of tropical medicine and hygiene · 2023Pooled it
- Article
- Substandard and Falsified Medicines, Regulatory Capacity and Public Health: A Narrative Review With a Focus on Africa.Public health challenges · 2026Review
- Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused byJAC-antimicrobial resistance · 2026Review
- Comparative Assessment of the Pharmaceutical Quality of Amoxicillin Capsules Marketed in Authorized and an Unregulated Point of Sale in Mexican Market.Therapeutic innovation & regulatory science · 2026Article
- Fedorov algorithm-optimized chemometric spectrophotometry for cefepime-tazobactam microanalysis in plasma and pharmaceuticals with integrated MA and NQS sustainability assessment.Scientific reports · 2026Article
- Quality evaluation of cephalexin, cefuroxime, and ceftriaxone medicines marketed in Addis Ababa city, Ethiopia with three tier level approach and anti-microbial assays.BMC pharmacology & toxicology · 2025Article
- Optimization of the Use of Generic Medications in Oncology: Improving Safety and Therapeutic Quality.Journal of clinical medicine · 2025Article
- Post-market quality monitoring of medicines in Christian Health Association of Ghana health institutions.Ghana medical journal · 2025Article
- Medicine quality assessment in Nepal using semi randomised sampling and evaluation of a small scale dissolution test and portable Raman spectrometers.Scientific reports · 2025Article
- Transnational Criminal Enterprise: a Qualitative Social Network Analysis of the Production and Trade in Falsified Medicines.Archives europeennes de sociologie. European journal of sociology. Europaisches Archiv fur Soziologie · 2025Article
- Substandard and falsified antibiotics are associated with antimicrobial resistance: a retrospective country-level analysis.BMJ global health · 2025Article
- 'Prevalence, experience and awareness of substandard and falsified medicines among the public and healthcare professionals in Jordan'.BMJ global health · 2025Article
- Article
- A Cost-Effective Liquid Chromatography Method with Ultraviolet Detection for Identity Screening and Assay of Injectable Antibiotics.Molecules (Basel, Switzerland) · 2025Article
- Effect of tropical climates on the quality of commonly used antibiotics: the protocol for a systematic review and meta-analysis.BMJ open · 2025Article
- Estimated prevalence of unregistered and falsified medicinal products in Malaysia: a nationwide cross-sectional study conducted from March to November 2023.Journal of pharmaceutical policy and practice · 2025Article
- Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal.Therapeutic advances in drug safety · 2025Article
- Breaking barriers: how generic drugs democratize mental health.Frontiers in pharmacology · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor-quality medicines present a serious public health problem, particularly in emerging economies and developing countries, and may have a significant impact on the national clinical and economic burden. Attention has largely focused on the increasing availability of deliberately falsified drugs, but substandard medicines are also reaching patients because of poor manufacturing and quality-control practices in the production of genuine drugs (either branded or generic). Substandard medicines are widespread and represent a threat to health because they can inadvertently lead to healthcare failures, such as antibiotic resistance and the spread of disease within a community, as well as death or additional illness in individuals. This article reviews the different aspects of substandard drug formulation that can occur (for example, pharmacological variability between drug batches or between generic and originator drugs, incorrect drug quantity and presence of impurities). The possible means of addressing substandard manufacturing practices are also discussed. A concerted effort is required on the part of governments, drug manufacturers, charities and healthcare providers to ensure that only drugs of acceptable quality reach the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.